CAR T cell
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
... The CTCAE CRS grading scale was then further modified to define mild, moderate, severe, and life- threatening CRS, regardless of the inciting agent, and to guide treatment recommendations [36]. This modified scale uses ...
12
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... for T cell ...of T cells ...and CAR-T cell persistence ...called T cell redirected for antigen-unrestricted cytokine-initiated killing (TRUCKs) encode genes for ...
20
CAR-T cell therapy in neuro-oncology: applications and toxicity
... CAR-T therapy has had promising results in hematological malignancies and has revolutionized the immunotherapy field in the last several years. There is a great hope that with the identification of the ...
12
Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors
... RR T cells had expanded such that they accounted for 36% of total live cells in ...SSTR2-negative T cell expansion, we then treated tumor-bearing mice with SR T cells at days 7, 10, 13, and 15 ...
18
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
... thelial cell and pericyte ...bi-specific CAR-T cell infusion, just at the onset of grade 3 neurotoxicity (unpublished ...receiving CAR-T cells, which should be attributable to a ...
10
T cell senescence and CAR-T cell exhaustion in hematological malignancies
... malignancies. CAR-T and TCR-T cell therapy makes use of functionally active T cells isolated from ...These T cells are reconstructed and expanded ex vivo to recognize specific ...
9
Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity
... on CAR-mediated inter- ...limits CAR T cell engraftment in the bone marrow for at least 3 d ...of CAR T cell trapping by circulating targets (B cells and tumors), we ...
12
CAR-T cell therapy: a potential new strategy against prostate cancer
... B cell lymphoma ...CD19-directed CAR-T cells for the treat- ment of relapsed/refractory pediatric and young-adult diffuse large B cell lymphoma (DLBCL), also sparking off research into solid ...
11
The expansion of targetable biomarkers for CAR T cell therapy
... vaccine, CAR T cells have been developed to directly target malignant cells expressing ...These CAR T cell therapies have shown delayed tumor growth, elim- ination of EGFRVIII+ tumor ...
23
Current Progress in CAR-T Cell Therapy for Solid Tumors
... affinity-tuned CAR. In recent years, studies have demonstrated that adjusting the CAR affinity of CAR-T cells and maintaining potent antitumor efficacy in vivo, could distinguish tumor cells ...
13
A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
... Mantle cell lymphoma (MCL) at stage IV B with deletion of TP53 gene by lymph node biopsy in local hospital at September, ...for CAR T cell therapy, a clinical trial of sequential infusion of ...
7
New development in CAR-T cell therapy
... targeted CAR [43, ...dual-signaling CAR or TanCAR compared to the unispecific CAR or pooling unispecific CAR when both antigens are expressed on the tumor cell surface [43, 45], ...
11
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
... surrounding CAR-T cell treat- ment, namely whether they have toxic effects and whether CAR-T cells are sustainable, have hindered its broad clinical ...effector T cells and the ...
8
Therapeutic potential of CAR-T cell-derived exosomes: a cell- free modality for targeted cancer therapy
... from CAR-T cells and the status of in vivo expansion of these cells cannot be appropriately controlled, which is the potential source of adverse events, such as CRS, cytokine storm and “on- target, ...
12
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
... NSG mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and were housed under standard housing conditions at the animal facilities in the Cleve- land Clinic Lerner Research Institute. The precursor to ...
12
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
... BCL2i, CAR T therapy offers a new opportunity that could not only replace allogeneic HCT in patients who would have been eligible, but could also be extended to older patients with a reasonable level of ...
6
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
... equilibrate T cell surface expression of ICOSBBz and BBz CARs using a less active promoter to drive BBz ...(26). T cells transduced with the modified pGK300-BBz LV displayed cell surface ...
18
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
... later, CAR or CAR +ICR-modified T cells were added to tumor cells to achieve a T cell:tumor cell ratio of 1:10 in the presence of 400 U/mL ...beads. T cells were then purified ...
13
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
... renal cell (40), rectal adenocarcinoma (41), and prostate cancer ...enhance CAR T cell activity. We used CAR T cells targeting human HER2 in transgenic mice engineered to ...
14
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
... (CD19 CAR–T cells) has produced a high rate of complete remission (CR) in adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (B-ALL) in small phase I ...
17